

1 **WHAT IS CLAIMED IS:**

- 2 1. A method for treating immune disorders comprising administering
3 CD30 or a biologically functional equivalent thereof to a human afflicted with
4 immune disorders.
- 5 2. The method as claimed in claim 1, wherein the CD30 or the
6 biologically functional equivalent thereof is administered intravenously.
- 7 3. The method as claimed in claim 1, wherein the CD30 or the
8 biologically functional equivalent thereof is administered locally.
- 9 4. The method as claimed in claim 1, wherein the CD30 or the
10 biologically functional equivalent thereof is a soluble protein.
- 11 5. The method as claimed in claim 1, wherein the biologically
12 functional equivalent is a soluble chimeric protein.
- 13 6. The method as claimed in claim 1, wherein the CD30 or the
14 biologically functional equivalent thereof is administered in the form of a
15 composition that additionally comprises a diluent, excipient or carrier.
- 16 7. The method as claimed in claim 1, wherein the immune disorders are
17 associated with T-cell activation.
- 18 8. The method as claimed in claim 1, wherein the immune disorders are
19 associated with T-cell proliferation.
- 20 9. A method for lowering the levels of T-cell activation and T-cell
21 proliferation in a human in need of lowering the levels of T-cell activation and
22 T-cell proliferation, which comprises administering to a human a
23 therapeutically effective amount of CD30 or a biologically functional
24 equivalent thereof.

1 10. The method as claimed in claim 9, wherein the biologically
2 functional equivalent is a chimeric antibody comprising an extracellular
3 domain of CD30 fused to an immunoglobulin heavy chain constant region
4 polypeptide.

5 11. The method as claimed in claim 9, wherein the T cell activation is
6 associated with T-cell production of IL-2.

7 12. The method as claimed in claim 9, wherein the T cell activation is
8 associated with T-cell expression of CD25.

9 13. The method as claimed in claim 9, wherein the T cell activation is
10 associated with T-cell expression of CD26.

11 14. The method as claimed in claim 9, wherein lowering the level of T
12 cell activation is associated with the decrease in the level of IL-2 production.

13 15. The method as claimed in claim 9, wherein the decrease in the level
14 of T-cell proliferation by a therapeutically effective amount of CD30 or a
15 biologically functional equivalent thereof is attenuated with IL-2
16 supplementation.

17 16. A pharmaceutical composition for treating immune disorders in a
18 human comprising a therapeutically effective amount of CD30 or a biologically
19 functional equivalent thereof and a pharmaceutically acceptable carrier,
20 excipient or diluent.

21 17. The pharmaceutical composition as claimed in claim 16, wherein
22 the CD30 or the biologically functional equivalent thereof is a soluble protein.

23 18. The pharmaceutical composition as claimed in claim 16, wherein
24 the biologically functional equivalent is a soluble chimeric protein.

- 1 19. The pharmaceutical composition as claimed in claim 16, wherein
2 the CD30 or the biologically functional equivalent binds to CD30 ligand.